Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model

Cancer Science

Volumn 101, Issue 11, 2010, Pages 2325-2332

  Wen, Yuan ^a   Wang, Chun Ting ^a   Ma, Tian Tai ^a   Li, Zhi Yong ^a   Zhou, Li Na ^b   Mu, Bo ^a   Leng, Fei ^a   Shi, Hua Shan ^a   Li, Ya Ou ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DNA VACCINE; FIBROBLAST ACTIVATION PROTEIN; TUMOR REJECTION ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLON CANCER; FEMALE; FIBROBLAST; LIFESPAN; LUNG METASTASIS; LYMPHOCYTOTOXICITY; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; GELATINASES; HUMANS; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; SERINE ENDOPEPTIDASES; SURVIVAL ANALYSIS; TUMOR BURDEN; VACCINES, DNA;

EID: 78049442950     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01695.x     Document Type: Article

References (39)

1. Marincola FM, Jaffee EM, Hicklin DJ et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
2. Cohen S, Regev A, Lavi S. Small polydispersed circular DNA (spcDNA) in human cells: association with genomic instability. Oncogene 1997; 14: 977-85.
3. Vitale M, Rezzani R, Rodella L et al. HLA class I antigen and transporter associated with antigen processing (TAPI and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res 1998; 58: 737-42.
4. Shaheen RM, Davis DW, Liu W et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999; 59: 5412-6.
5. Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell 2003; 3: 17-22.
6. Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res 2005; 65: 11156-63.
7. Loeffler M, Krüger JA, Niethammer AG et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006; 116: 1955-62.
8. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 375-9.
9. Serenella M, Pupa SM, Forti S et al. New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 2002; 192: 259-67.
10. Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer. Science 2002; 296: 1046-9.
11. Singh S, Ross SR, Acena M et al. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med 1992; 175: 139-46.
12. Schüler T, Körnig S, Blankenstein T. Tumor rejection by modulation of tumor stromal fibroblasts. J Exp Med 2003; 198: 1487-93.
13. Bhowmick NA, Chytil A, Plieth D et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004; 303: 848-51.
14. Ibe S, Qin Z, Schüler T, Preiss S, Blankenstein T. Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med 2001; 194: 1549-59.
15. O'Connor DS, Schechner JS, Adida C et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 2000; 156: 393-8.
16. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-103.
17. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 1998; 64: 275-90.
18. Muraoka RS, Dumont N, Ritter CA et al. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002; 109: 1551-9.
19. Park JE, Lenter MC, Zimmermann RN et al. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 1999; 274: 36505-12.
20. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 1990; 87: 7235-9.
21. Cheng JD, Dunbrack RL Jr, Valianou M et al. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res 2002; 62: 4767-72.
22. Henry LR, Lee HO, Lee JS et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 2007; 13(6): 1736-41.
23. Cheng JD, Valianou M, Canutescu AA et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol Cancer Ther 2005; 4: 351-60.
24. Niedermeyer J, Scanlan MJ, Garin-Chesa P et al. Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers. Int J Cancer 1997; 71: 383-9.
25. Goldstein LA, Ghersi G, Piñeiro-Sánchez ML et al. Molecular cloning of seprase: a serine integral membrane protease from human melanoma. Bba-Mol Basis Dis 1997; 1361: 9-11.
26. Scanlan MJ, Raj BK, Calvo B et al. Molecular cloning of fibroblast activation protein α, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA 1994; 91: 5657-61.
27. Rettig WJ, Garin-Chesa P, Healey JH et al. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res 1993; 53: 3327-35.
28. Fassnacht M, Lee J, Milazzo C, Boczkowski D et al. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. Clin Cancer Res 2005; 11: 5566-71.
29. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Paylakis GN. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 1997; 15: 647-52.
30. Wei Y, Zhao X, Kariya Y, Fukata H et al. Induction of autologous tumor killing by heat treatment of fresh human tumor cells: involvement of gamma delta T cells and heat shock protein 70. Cancer Res 1996; 56: 1104-10.
31. Wang YS, Wang GQ, Wen YJ et al. Immunity against tumor angiogenesis induced by a fusion vaccine with murine β-Defensin 2 and mFlk-1. Clin Cancer Res 2007; 13: 6779-87.
32. Wei Y-Q, Wang Q-R, Zhao X et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000; 6: 1160-6.
33. Horton HM, Anderson D, Hernandez P et al. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon α Proc Natl Acad Sci USA 1999; 96: 1553-8.
34. Liu JY, Wei YQ, Yang L et al. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 2003; 102: 1815-23.
35. Roskelley CD, Bissell MJ. The dominance of the microenvironment in breast and ovarian cancer. Semin Cancer Biol 2002; 12: 97-104.
36. Hofheinz RD, Al-Batran SE, Hartmann F et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 2003; 26: 44-8.
37. Scott AM, Wiseman G, Welt S et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein positive cancer. Clin Cancer Res 2003; 9: 1639-47.
38. Niedermeyer J, Kriz M, Hilberg F et al. Targeted disruption of mouse fibroblast activation protein. Mol Cell Biol 2000; 20: 1089-94.
39. Tanswell P, Garin-Chesa PRettig WJ et al. Population pharmacokinetics of anti-fibroblast activation protein monoclonal antibody F19 in cancer patients. Br J Clin Pharmacol. 221 2001; 51: 177-80.